search
Back to results

Exercise, Cancer and Cognition: The ECCO-Study (ECCO)

Primary Purpose

Breast Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
High-Intensity-Interval-Training
General Physical Activity Recommendations
Sponsored by
Johannes Kepler University of Linz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Breast Cancer focused on measuring Breast, Cancer, CRCI, Chemobrain, Cognition, Exercise, High-Intensity-Interval-Training

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically confirmed breast cancer and planned neo- and adjuvant chemotherapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Age 18 - 70 years
  • Adequate hematologic functions 28d prior to randomization (Platelet count over 50 G/L, Hemoglobin over 8 g/dL)
  • Able to perform exercise according to protocol
  • Signed informed consent prior to randomization
  • Fluid in German

Exclusion Criteria:

  • Significant comorbid conditions precluding participation in a physical activity program (investigators decision)
  • Anamnestic cognitive impairment or psychological disorders
  • Disabled patients unable to participate in the physical activity program or performing cognitive tests
  • Vigorous physical activity of >300 minutes weekly within the last year before diagnosis of breast cancer 8.3
  • Patients unwilling to complete endurance exercise or complete all questionnaires related to the study
  • Past or current history of other malignant neoplasms other than breast cancer in the last 5 years except basal cell carcinoma of the skin and/or in situ carcinoma of the cervix
  • Clinically significant cardiovascular disease (including myocardial infarction < 6 month before randomization, unstable angina, symptomatic congestive heart failure NYHA II-IV, serious uncontrolled cardiac arrhythmia, preexcitation syndromes (eg Wolff-Parkinson-White-Syndrome), high grade or complete AV-Block, left bundle branch block, permanent pacemaker stimulation, uncontrolled hypertension (systolic blood pressure >160 mmHg), aortic valve stenosis, moderate to high-grade valve disease, endo-, myo-, pericarditis, acute aortic dissection, acute pulmonary embolism, acute phlebothrombosis of the lower extremity
  • Current pregnancy or plans to become pregnant within the next year after study entry (Pregnancy tests are included in clinical routine before every chemotherapy)
  • Signs of severe morphological brain damage in the baseline screening

Sites / Locations

  • Kepler University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Arm A: Exercise intervention arm

Arm B: Control arm

Arm Description

Outcomes

Primary Outcome Measures

Cognition
The primary endpoint is measured by the changes in the total score of the California Verbal Learning Test (CVLT), measured 12 months after baseline assessment. Total points of the score are 176 pts., with less points indicating a worse outcome/ cognitive impairment and more points a better outcome/ cognitive function.

Secondary Outcome Measures

Hippocampal Volume
Devation of hippocampal volume measured 12 months after baseline assessment.

Full Information

First Posted
March 8, 2020
Last Updated
March 10, 2021
Sponsor
Johannes Kepler University of Linz
Collaborators
German Sport University, Cologne, University of Graz, Charite University, Berlin, Germany, Charles University, Czech Republic
search

1. Study Identification

Unique Protocol Identification Number
NCT04789187
Brief Title
Exercise, Cancer and Cognition: The ECCO-Study
Acronym
ECCO
Official Title
Randomized Controlled Trial of Simultaneous Exercise During Neo-/Adjuvant Chemotherapy in Breast Cancer Patients and Its Effects on Neurocognition
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2019 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Johannes Kepler University of Linz
Collaborators
German Sport University, Cologne, University of Graz, Charite University, Berlin, Germany, Charles University, Czech Republic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The "ECCO"-study evaluates the efficacy of simultaneous controlled exercise during neo/-adjuvant chemotherapy in breast cancer patients and its effects on neurocognition. In this study the investigators examine the benefits of the individualized high intensity training program on a cancer related cognitive impairment. Changes in patients' cognition are evaluated by neuropsychological testing. Possible structural changes are detected with MRI volumetry. Biomarkers connected to Cancer Related Cognitive Impairment (CRCI) and chemotherapy related inflammatory processes which impair cognition, respectively, will be assessed.
Detailed Description
Background: Epidemiological research indicates that increased levels of physical activity are associated with decreased breast cancer risk and mortality. Thereby, exercise programs can substantially increase patients' quality of life during and after treatment. Up to 80% of breast cancer patients demonstrate a decrease in their cognitive capacity, summarized as the symptom-complex "Cancer Related Cognitive Impairment (CRCI)". Most frequently reported impairments are mild to moderate deficits in processing speed, attention, memory and executive functions. In about 35% of affected patients, cognitive symptoms persist for months, or even years, after completion of medical treatment, impairing daily functioning, limiting ability to return to work and decreasing overall quality of life. Recent studies indicate a key role of inflammatory pathways in the CRCI genesis. Attention to physical activity therefore as a potential supportive care option is increasing. Anyhow, evidence for positive effects of exercise on CRCI is still lacking. Patients and Methods: This prospective, two-arm, 1:1 randomized, controlled trial aims to investigate the influence of high-intensity training interventions accompanying neo/-adjuvant chemotherapy on CRCI in 126 patients with early breast cancer on cognitive performance measured by the California Verbal Learning Test (CVLT). Secondary endpoints include subjective markers and tests for cognitive performance and inflammatory biomarkers as TNF-α, IL-6, IL-1α, IL-1ß which are suspected to be involved in the pathogenesis of CRCI. As cognitive impairments are believed to be connected to either functional and/or morphological hippocampal damage due to chemotherapy, head MRIs and hippocampal volume measurements will be performed. In addition to a heart rate controlled home-based endurance and strength training for one year, participants in the intervention group will perform a supervised high-intensity interval training (HIIT) exercise program at least once a week. This study will help to clarify whether a long-term supervised exercise intervention program affects CRCI in breast cancer patients and help to reason underlying mechanisms and the pathogenesis of the chemobrain.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
Breast, Cancer, CRCI, Chemobrain, Cognition, Exercise, High-Intensity-Interval-Training

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized Controlled Trial
Masking
ParticipantOutcomes Assessor
Masking Description
Pseudonymization
Allocation
Randomized
Enrollment
126 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm A: Exercise intervention arm
Arm Type
Active Comparator
Arm Title
Arm B: Control arm
Arm Type
Placebo Comparator
Intervention Type
Procedure
Intervention Name(s)
High-Intensity-Interval-Training
Intervention Description
Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.
Intervention Type
Procedure
Intervention Name(s)
General Physical Activity Recommendations
Intervention Description
Patients will be given general physical activity recommendations during chemotherapy.
Primary Outcome Measure Information:
Title
Cognition
Description
The primary endpoint is measured by the changes in the total score of the California Verbal Learning Test (CVLT), measured 12 months after baseline assessment. Total points of the score are 176 pts., with less points indicating a worse outcome/ cognitive impairment and more points a better outcome/ cognitive function.
Time Frame
12 month
Secondary Outcome Measure Information:
Title
Hippocampal Volume
Description
Devation of hippocampal volume measured 12 months after baseline assessment.
Time Frame
12 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed breast cancer and planned neo- and adjuvant chemotherapy Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Age 18 - 70 years Adequate hematologic functions 28d prior to randomization (Platelet count over 50 G/L, Hemoglobin over 8 g/dL) Able to perform exercise according to protocol Signed informed consent prior to randomization Fluid in German Exclusion Criteria: Significant comorbid conditions precluding participation in a physical activity program (investigators decision) Anamnestic cognitive impairment or psychological disorders Disabled patients unable to participate in the physical activity program or performing cognitive tests Vigorous physical activity of >300 minutes weekly within the last year before diagnosis of breast cancer 8.3 Patients unwilling to complete endurance exercise or complete all questionnaires related to the study Past or current history of other malignant neoplasms other than breast cancer in the last 5 years except basal cell carcinoma of the skin and/or in situ carcinoma of the cervix Clinically significant cardiovascular disease (including myocardial infarction < 6 month before randomization, unstable angina, symptomatic congestive heart failure NYHA II-IV, serious uncontrolled cardiac arrhythmia, preexcitation syndromes (eg Wolff-Parkinson-White-Syndrome), high grade or complete AV-Block, left bundle branch block, permanent pacemaker stimulation, uncontrolled hypertension (systolic blood pressure >160 mmHg), aortic valve stenosis, moderate to high-grade valve disease, endo-, myo-, pericarditis, acute aortic dissection, acute pulmonary embolism, acute phlebothrombosis of the lower extremity Current pregnancy or plans to become pregnant within the next year after study entry (Pregnancy tests are included in clinical routine before every chemotherapy) Signs of severe morphological brain damage in the baseline screening
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Milan R Vosko, MD, PhD
Phone
+435768083
Ext
6672
Email
milan.vosko@kepleruniklinikum.at
First Name & Middle Initial & Last Name or Official Title & Degree
David Kiesl, MD
Phone
+43768083
Ext
1610
Email
david.kiesl@kepleruniklinikum.at
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Milan R Vosko, MD, PhD
Organizational Affiliation
Johannes Kepler University of Linz
Official's Role
Study Chair
Facility Information:
Facility Name
Kepler University Hospital
City
Linz
State/Province
Upper Austria
ZIP/Postal Code
4020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Kiesl, MD
Phone
+435768083
Ext
1610
Email
david.kiesl@kepleruniklinikum.at
First Name & Middle Initial & Last Name & Degree
Milan R Vosko, MD, PhD
Phone
+43768083
Ext
6672
Email
milan.vosko@kepleruniklinikum.at

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35401389
Citation
Kiesl D, Kuzdas-Sallaberger M, Fuchs D, Brunner S, Kommenda R, Tischler C, Hornich H, Akbari K, Kellermair J, Blessberger H, Ocenasek H, Hofmann P, Zimmer P, Vosko MR. Protocol for the Exercise, Cancer and Cognition - The ECCO-Study: A Randomized Controlled Trial of Simultaneous Exercise During Neo-/Adjuvant Chemotherapy in Breast Cancer Patients and Its Effects on Neurocognition. Front Neurol. 2022 Mar 25;13:777808. doi: 10.3389/fneur.2022.777808. eCollection 2022.
Results Reference
derived

Learn more about this trial

Exercise, Cancer and Cognition: The ECCO-Study

We'll reach out to this number within 24 hrs